FDA streamlines patient access information

Share this article:

FDA is making it easier for patients to participate in the regulatory process with its new Patient Network website, which brings together info previously scattered across various websites into a central, streamlined interface. The new site invites patients to become patient representatives at advisory committee meetings and offers them the opportunity to submit comments on regulations. The ease comes from allowing consumers to use the Patient Network site as the springboard to pre-existing sites like Regulations.gov, saving the steps of site awareness and location. The site was provided through the regulator's Office of Health and Constituent Services office, which is charged with ensuring patient perspectives are considered during drug development.

“This website will open new channels of communication with the public, such as live chats with senior agency officials,” FDA Commissioner Margaret Hamburg wrote in a blog post about the network. 

The patient page also invites readers to join clinical trials, find treatment options and to see what's been recently approved. It also includes a FAQ section that addresses questions like why drug approvals take a while to go through and what advisory committees do.

Hamburg also wrote that the site's significance goes beyond providing an easy way for patients and caregivers to seek out safety information and provide regulatory input, writing that the Patient Network “provides a new model for FDA to follow in making its inner workings transparent to the public.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...